We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

COR:NYSECencora, Inc. Analysis

Data as of 2026-06-13 - not real-time

$281.67

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Cencora (COR) trades at $281.67, comfortably above its 20‑day SMA of 270 but below the 50‑day SMA of 289 and far under the 200‑day SMA of 325, indicating a short‑term pull‑back within a longer‑term downtrend. The RSI of 55 suggests neutral momentum, while the MACD histogram is positive (+3.53) and the signal line turns bullish, hinting at a possible technical bounce toward the near resistance at $284.93. Volatility is elevated at 60% over the past 30 days and beta is essentially flat (‑0.05), so price swings are driven more by company‑specific factors than market moves. Fundamentals show a modest 3.8% YoY revenue increase to $78.36 B, a PE of 21.6 versus the industry average of 24.8 (undervalued on earnings), but razor‑thin margins (gross 3.8%, operating 1.7%) and a high debt‑to‑equity ratio of 421, raising concerns about financial leverage. The dividend yield is low at 0.85% with a payout ratio of 17.6%, indicating sustainability but limited income appeal. Analysts forecast an upside of ~24% versus the current price, while the DCF fair‑value of $61.30 appears dramatically out of line, underscoring valuation model uncertainty. Recent material news includes Q1 earnings that met expectations, a Q2 miss that sent the stock down 16.7% pre‑market, and an ongoing securities class‑action investigation, all of which add short‑term pressure. Conversely, Wells Fargo maintains an overweight rating, and the company’s buyback program and raised EPS outlook signal management confidence. In this mixed environment, the stock sits on a support of $255.07 with limited downside cushion but also faces headroom to the $284.93 resistance before broader market sentiment and earnings trends dictate direction.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Technical bearish bias (price below 50‑day SMA, near resistance)
  • Q2 earnings miss and pre‑market sell‑off
  • Class‑action investigation adding uncertainty

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Undervalued PE relative to industry peers
  • Projected upside of ~24% and overweight rating from Wells Fargo
  • Revenue growth and management’s buyback/EPS raise

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Low beta and sustainable dividend payout
  • Stable healthcare distribution sector with modest growth
  • Potential margin improvement and cash‑flow generation despite high leverage

Key Metrics & Analysis

Financial Health

Revenue Growth3.80%
Profit Margin0.78%
P/E Ratio21.6
ROE107.13%
ROA3.49%
Debt/Equity420.99
P/B Ratio16.1
Op. Cash Flow$2.3B
Free Cash Flow$-318246112
Industry P/E24.8

Technical Analysis

TrendBearish
RSI55.1
Support$255.07
Resistance$284.93
MA 20$270.11
MA 50$289.38
MA 200$325.12
MACDBullish
VolumeDecreasing
Fear & Greed Index89.86

Valuation

Fair Value$61.30
Target Price$350.58
Upside/Downside24.47%
GradeUndervalued
TypeBlend
Dividend Yield0.85%

Risk Assessment

Beta-0.05
Volatility60.41%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.